References
- Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- Shipp MA, Anderson JR, Armitage JO, Bonnadonna G, Brittinger GA. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
- Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res 2003;9:722–728.
- Linderoth J, Ehinger M, Jerkeman M, et al CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:1774–1779.
- Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
- Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppa S. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol 2009;82:364–372.
- Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991. p. 394.
- Nyman H, Adde M, Karjalainen-Lindsberg ML, et al Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930–4935.
- Fu K, Weisenburger DD, Choi WW, et al Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587–4594.
- Wilson WH, Dunleavy K, Pittaluga S, et al Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717–2724.
- Winter JN, Weller EA, Horning SJ, et al Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207–4213.
- de Jong D, Xie W, Rosenwald A, et al Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009;62:128–138.
- van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2–17.
- Vestal RE, Wingett D, Freeman G. Expression of CD40 in breast, colon, lung and ovarian tumours. Proc Am Assoc Cancer Res 1997;38:230 (Abstract 1550).
- Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478–480.
- Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007;13:1083–1088.
- French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548–553.
- Planken EV, Dijkstra NH, Willemze R, Kluin-Nelemans JC. Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the ‘CD40 system’. Leukemia 1996;10:488–493.
- Funakoshi S, Longo DL, Beckwith M, et al Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83:2787–2794.
- Szocinski JL, Khaled AR, Hixon J, et al Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 2002;100:217–223.
- Saito M, Gao J, Basso K, et al A signaling pathway mediating down regulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007;12:280–292.
- Parekh S, Polo JM, Shaknovich R, et al BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 2007;110:2067–2074.